Stock Traders Buy High Volume of TESARO Call Options (TSRO)
TESARO Inc (NASDAQ:TSRO) was the recipient of some unusual options trading activity on Friday. Investors acquired 4,766 call options on the stock. This represents an increase of approximately 1,698% compared to the average volume of 265 call options.
A number of equities research analysts recently weighed in on TSRO shares. BidaskClub upgraded shares of TESARO from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 23rd. Cann restated a “buy” rating and issued a $199.00 target price on shares of TESARO in a report on Friday, September 8th. Citigroup restated a “buy” rating and issued a $216.00 target price on shares of TESARO in a report on Monday, September 11th. Oppenheimer restated a “buy” rating and issued a $199.00 target price on shares of TESARO in a report on Sunday, September 10th. Finally, Wedbush restated an “outperform” rating and issued a $160.00 target price on shares of TESARO in a report on Monday, September 11th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $159.39.
In other news, SVP Martin H. Jr. Huber sold 829 shares of the company’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $85.24, for a total transaction of $70,663.96. Following the transaction, the senior vice president now owns 8,101 shares in the company, valued at $690,529.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Martin H. Jr. Huber sold 592 shares of the company’s stock in a transaction dated Friday, September 22nd. The stock was sold at an average price of $118.60, for a total transaction of $70,211.20. Following the completion of the sale, the senior vice president now owns 6,943 shares in the company, valued at approximately $823,439.80. The disclosure for this sale can be found here. 34.60% of the stock is currently owned by corporate insiders.
Shares of TESARO (NASDAQ TSRO) opened at $76.90 on Wednesday. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.73 and a quick ratio of 4.35. TESARO has a one year low of $76.74 and a one year high of $192.94.
TESARO (NASDAQ:TSRO) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.16) by $0.69. The firm had revenue of $142.77 million during the quarter, compared to analyst estimates of $130.57 million. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The company’s revenue for the quarter was up 740.3% on a year-over-year basis. During the same quarter last year, the business posted ($1.72) EPS. equities analysts forecast that TESARO will post -8.17 EPS for the current fiscal year.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.